| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 25 | 2024 | 167 | 7.060 |
Why?
|
| Substance-Related Disorders | 29 | 2022 | 434 | 5.910 |
Why?
|
| Analgesics, Opioid | 34 | 2024 | 243 | 5.660 |
Why?
|
| Patient Protection and Affordable Care Act | 7 | 2020 | 42 | 3.120 |
Why?
|
| Delivery of Health Care, Integrated | 11 | 2024 | 531 | 2.670 |
Why?
|
| Buprenorphine | 7 | 2023 | 48 | 2.660 |
Why?
|
| HIV Infections | 19 | 2024 | 694 | 2.550 |
Why?
|
| Humans | 111 | 2024 | 17611 | 2.350 |
Why?
|
| Adult | 67 | 2024 | 7598 | 2.210 |
Why?
|
| Female | 85 | 2024 | 12608 | 2.100 |
Why?
|
| Male | 73 | 2024 | 10008 | 2.020 |
Why?
|
| Mental Disorders | 7 | 2024 | 280 | 1.970 |
Why?
|
| Substance Abuse Treatment Centers | 12 | 2012 | 75 | 1.900 |
Why?
|
| California | 31 | 2024 | 2284 | 1.840 |
Why?
|
| Middle Aged | 54 | 2024 | 7911 | 1.740 |
Why?
|
| Chronic Pain | 10 | 2024 | 127 | 1.710 |
Why?
|
| Alcoholism | 10 | 2024 | 347 | 1.610 |
Why?
|
| Patient Acceptance of Health Care | 8 | 2024 | 382 | 1.500 |
Why?
|
| Electronic Health Records | 14 | 2024 | 681 | 1.480 |
Why?
|
| Primary Health Care | 16 | 2024 | 766 | 1.430 |
Why?
|
| Marijuana Abuse | 5 | 2024 | 40 | 1.430 |
Why?
|
| Marijuana Use | 7 | 2024 | 36 | 1.340 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 358 | 1.260 |
Why?
|
| Opiate Substitution Treatment | 7 | 2024 | 44 | 1.240 |
Why?
|
| Young Adult | 27 | 2024 | 2427 | 1.230 |
Why?
|
| Ambulatory Care | 7 | 2012 | 244 | 1.220 |
Why?
|
| Adolescent | 32 | 2024 | 3651 | 1.220 |
Why?
|
| Telemedicine | 4 | 2023 | 182 | 1.160 |
Why?
|
| Pain | 10 | 2024 | 79 | 1.090 |
Why?
|
| Aged | 30 | 2024 | 6095 | 1.060 |
Why?
|
| Drug Overdose | 5 | 2020 | 56 | 1.060 |
Why?
|
| Health Services Accessibility | 7 | 2020 | 289 | 1.040 |
Why?
|
| Health Care Costs | 3 | 2017 | 228 | 1.020 |
Why?
|
| Registries | 3 | 2018 | 471 | 1.020 |
Why?
|
| Adolescent Behavior | 4 | 2024 | 127 | 1.010 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 415 | 0.970 |
Why?
|
| Retrospective Studies | 21 | 2024 | 2447 | 0.970 |
Why?
|
| Prenatal Care | 2 | 2024 | 128 | 0.920 |
Why?
|
| Radiculopathy | 1 | 2023 | 5 | 0.910 |
Why?
|
| Insurance Coverage | 3 | 2020 | 106 | 0.900 |
Why?
|
| United States | 22 | 2022 | 3956 | 0.890 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 27 | 0.880 |
Why?
|
| Health Services | 3 | 2016 | 112 | 0.810 |
Why?
|
| Cohort Studies | 15 | 2024 | 2570 | 0.770 |
Why?
|
| Alcohol Drinking | 4 | 2024 | 368 | 0.750 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2021 | 13 | 0.740 |
Why?
|
| Social Class | 2 | 2023 | 120 | 0.740 |
Why?
|
| Marijuana Smoking | 3 | 2024 | 52 | 0.730 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 1322 | 0.710 |
Why?
|
| Health Policy | 2 | 2018 | 122 | 0.710 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 22 | 0.700 |
Why?
|
| Treatment Outcome | 15 | 2021 | 1259 | 0.690 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 124 | 0.680 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2024 | 330 | 0.630 |
Why?
|
| Family | 2 | 2017 | 111 | 0.630 |
Why?
|
| Alcohol-Related Disorders | 2 | 2017 | 55 | 0.620 |
Why?
|
| Prescription Drug Misuse | 1 | 2018 | 11 | 0.610 |
Why?
|
| Self-Help Groups | 3 | 2013 | 30 | 0.590 |
Why?
|
| Patient Admission | 1 | 2017 | 72 | 0.580 |
Why?
|
| Drug Users | 1 | 2017 | 7 | 0.570 |
Why?
|
| Women's Health Services | 2 | 2008 | 20 | 0.570 |
Why?
|
| Depression | 7 | 2017 | 502 | 0.570 |
Why?
|
| Outpatients | 4 | 2023 | 107 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2009 | 93 | 0.550 |
Why?
|
| Smoking | 2 | 2017 | 483 | 0.550 |
Why?
|
| Self Report | 7 | 2024 | 251 | 0.550 |
Why?
|
| Prevalence | 10 | 2024 | 884 | 0.550 |
Why?
|
| Income | 1 | 2017 | 90 | 0.550 |
Why?
|
| Inpatients | 1 | 2017 | 81 | 0.550 |
Why?
|
| Medical Marijuana | 3 | 2022 | 23 | 0.540 |
Why?
|
| Cannabis | 5 | 2024 | 78 | 0.540 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 1900 | 0.520 |
Why?
|
| Disease Management | 1 | 2016 | 135 | 0.520 |
Why?
|
| Analgesics | 3 | 2022 | 27 | 0.510 |
Why?
|
| Deductibles and Coinsurance | 1 | 2016 | 30 | 0.510 |
Why?
|
| Mental Health Services | 3 | 2024 | 154 | 0.510 |
Why?
|
| Pain Management | 5 | 2024 | 58 | 0.500 |
Why?
|
| Insurance, Health | 2 | 2016 | 181 | 0.490 |
Why?
|
| Patient Compliance | 6 | 2013 | 298 | 0.480 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 710 | 0.470 |
Why?
|
| Legislation, Drug | 2 | 2024 | 10 | 0.470 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 37 | 0.460 |
Why?
|
| Tobacco Use Cessation | 2 | 2017 | 22 | 0.450 |
Why?
|
| Patient Participation | 3 | 2024 | 133 | 0.450 |
Why?
|
| Drug Prescriptions | 5 | 2017 | 151 | 0.450 |
Why?
|
| Hospitalization | 2 | 2024 | 797 | 0.430 |
Why?
|
| Social Support | 2 | 2012 | 203 | 0.430 |
Why?
|
| Hallucinogens | 2 | 2024 | 23 | 0.420 |
Why?
|
| Sex Factors | 9 | 2017 | 643 | 0.410 |
Why?
|
| Pandemics | 6 | 2024 | 287 | 0.410 |
Why?
|
| Friends | 1 | 2012 | 10 | 0.400 |
Why?
|
| Health Care Surveys | 5 | 2022 | 230 | 0.400 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 42 | 0.400 |
Why?
|
| Private Sector | 3 | 2007 | 15 | 0.400 |
Why?
|
| Peer Group | 1 | 2012 | 48 | 0.390 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 3 | 2021 | 5 | 0.390 |
Why?
|
| Methadone | 2 | 2008 | 10 | 0.370 |
Why?
|
| Accreditation | 2 | 2008 | 5 | 0.370 |
Why?
|
| State Health Plans | 1 | 2010 | 35 | 0.360 |
Why?
|
| Risk Factors | 11 | 2018 | 3325 | 0.350 |
Why?
|
| Neoplasms | 4 | 2011 | 438 | 0.350 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 80 | 0.330 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2009 | 63 | 0.330 |
Why?
|
| Medicaid | 3 | 2022 | 186 | 0.320 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 1309 | 0.320 |
Why?
|
| Research Design | 2 | 2021 | 374 | 0.310 |
Why?
|
| Pregnancy | 5 | 2024 | 1494 | 0.310 |
Why?
|
| Depressive Disorder | 4 | 2018 | 222 | 0.300 |
Why?
|
| Respiratory Insufficiency | 2 | 2024 | 17 | 0.290 |
Why?
|
| Narcotics | 1 | 2007 | 7 | 0.290 |
Why?
|
| Self Care | 1 | 2008 | 163 | 0.290 |
Why?
|
| Comorbidity | 4 | 2017 | 594 | 0.290 |
Why?
|
| Licensure | 1 | 2007 | 5 | 0.280 |
Why?
|
| Psychotherapy | 1 | 2007 | 58 | 0.280 |
Why?
|
| Papillomavirus Infections | 2 | 2020 | 133 | 0.270 |
Why?
|
| Managed Care Programs | 3 | 2010 | 325 | 0.270 |
Why?
|
| Women's Health | 1 | 2007 | 200 | 0.270 |
Why?
|
| Age Factors | 8 | 2024 | 917 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 169 | 0.260 |
Why?
|
| Prescription Drugs | 2 | 2020 | 31 | 0.250 |
Why?
|
| Consensus | 2 | 2024 | 41 | 0.240 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 197 | 0.240 |
Why?
|
| Child | 5 | 2022 | 2474 | 0.240 |
Why?
|
| Cannabinoids | 1 | 2024 | 6 | 0.240 |
Why?
|
| Vomiting | 1 | 2024 | 12 | 0.240 |
Why?
|
| Fentanyl | 1 | 2024 | 1 | 0.240 |
Why?
|
| Commerce | 1 | 2024 | 48 | 0.230 |
Why?
|
| Regression Analysis | 3 | 2017 | 297 | 0.230 |
Why?
|
| Headache | 1 | 2023 | 14 | 0.230 |
Why?
|
| Back Pain | 1 | 2023 | 33 | 0.230 |
Why?
|
| Logistic Models | 6 | 2017 | 926 | 0.220 |
Why?
|
| Prescriptions | 1 | 2023 | 27 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 55 | 0.220 |
Why?
|
| Ecological Momentary Assessment | 1 | 2023 | 3 | 0.220 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 26 | 0.220 |
Why?
|
| Efficiency, Organizational | 1 | 2003 | 32 | 0.220 |
Why?
|
| Ethnic Groups | 3 | 2009 | 485 | 0.210 |
Why?
|
| Insurance | 1 | 2022 | 5 | 0.210 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 17 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2024 | 254 | 0.210 |
Why?
|
| Behavior, Addictive | 1 | 2022 | 12 | 0.210 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 24 | 0.210 |
Why?
|
| Ownership | 3 | 2008 | 15 | 0.210 |
Why?
|
| Patient Discharge | 1 | 2024 | 154 | 0.200 |
Why?
|
| Cultural Diversity | 1 | 2002 | 17 | 0.200 |
Why?
|
| Crisis Intervention | 1 | 2022 | 16 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 57 | 0.200 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 568 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 630 | 0.200 |
Why?
|
| HIV Seropositivity | 3 | 2006 | 31 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 69 | 0.190 |
Why?
|
| Quality of Life | 2 | 2024 | 507 | 0.190 |
Why?
|
| Nurse Administrators | 1 | 2021 | 7 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2021 | 33 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2022 | 57 | 0.190 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 98 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 86 | 0.180 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 57 | 0.180 |
Why?
|
| Community Health Services | 1 | 2021 | 83 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2020 | 13 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 85 | 0.180 |
Why?
|
| Case-Control Studies | 3 | 2020 | 1115 | 0.180 |
Why?
|
| Hepatitis C | 1 | 2021 | 65 | 0.180 |
Why?
|
| Time Factors | 7 | 2013 | 1086 | 0.180 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 91 | 0.170 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 4 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 6 | 0.170 |
Why?
|
| Social Environment | 2 | 2012 | 88 | 0.170 |
Why?
|
| Demography | 2 | 2012 | 101 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 6 | 0.170 |
Why?
|
| Mortality | 2 | 2017 | 117 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2013 | 178 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 56 | 0.170 |
Why?
|
| Postoperative Care | 1 | 2019 | 20 | 0.170 |
Why?
|
| Motivation | 2 | 2012 | 130 | 0.170 |
Why?
|
| Length of Stay | 2 | 2012 | 181 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2019 | 27 | 0.170 |
Why?
|
| Anti-HIV Agents | 2 | 2011 | 155 | 0.170 |
Why?
|
| Cesarean Section | 1 | 2019 | 30 | 0.170 |
Why?
|
| Long-Term Care | 4 | 2015 | 22 | 0.170 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.160 |
Why?
|
| HIV Seronegativity | 2 | 2006 | 9 | 0.160 |
Why?
|
| Mental Health | 2 | 2012 | 165 | 0.160 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 40 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2016 | 190 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 1210 | 0.160 |
Why?
|
| Odds Ratio | 5 | 2022 | 671 | 0.160 |
Why?
|
| Age Distribution | 2 | 2016 | 246 | 0.160 |
Why?
|
| Drug Utilization | 4 | 2015 | 127 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 119 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2020 | 113 | 0.160 |
Why?
|
| Dyslipidemias | 1 | 2009 | 62 | 0.150 |
Why?
|
| Child Care | 2 | 2008 | 11 | 0.150 |
Why?
|
| Health Services Research | 3 | 2020 | 231 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2019 | 189 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2024 | 1267 | 0.150 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 33 | 0.140 |
Why?
|
| Continental Population Groups | 1 | 2009 | 302 | 0.140 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 100 | 0.140 |
Why?
|
| Clinical Coding | 1 | 2017 | 11 | 0.140 |
Why?
|
| Forecasting | 1 | 2017 | 75 | 0.140 |
Why?
|
| Smoking Prevention | 1 | 2017 | 54 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 49 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2016 | 4 | 0.140 |
Why?
|
| Oxycodone | 1 | 2016 | 2 | 0.140 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 85 | 0.140 |
Why?
|
| Washington | 3 | 2017 | 374 | 0.130 |
Why?
|
| Human papillomavirus 16 | 1 | 2006 | 7 | 0.130 |
Why?
|
| HIV-1 | 1 | 2006 | 70 | 0.130 |
Why?
|
| HIV | 1 | 2006 | 26 | 0.130 |
Why?
|
| Incidence | 3 | 2013 | 1255 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2016 | 64 | 0.130 |
Why?
|
| Cost Sharing | 1 | 2016 | 30 | 0.130 |
Why?
|
| Chronic Disease | 4 | 2012 | 428 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 65 | 0.130 |
Why?
|
| Organizational Affiliation | 2 | 2007 | 2 | 0.130 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 95 | 0.130 |
Why?
|
| Algorithms | 1 | 2017 | 233 | 0.130 |
Why?
|
| Anxiety | 1 | 2016 | 150 | 0.130 |
Why?
|
| Psychometrics | 3 | 2012 | 121 | 0.120 |
Why?
|
| Mass Screening | 2 | 2022 | 661 | 0.120 |
Why?
|
| Health Personnel | 1 | 2015 | 124 | 0.120 |
Why?
|
| Patients | 1 | 2014 | 34 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1409 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 125 | 0.100 |
Why?
|
| Telephone | 3 | 2022 | 161 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 18 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 77 | 0.100 |
Why?
|
| Documentation | 2 | 2022 | 42 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2012 | 35 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 64 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2022 | 218 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2012 | 141 | 0.090 |
Why?
|
| Health Status | 1 | 2012 | 298 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2012 | 244 | 0.080 |
Why?
|
| Religion | 1 | 2009 | 14 | 0.080 |
Why?
|
| Asthma | 1 | 2012 | 385 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 105 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2014 | 237 | 0.080 |
Why?
|
| Health Surveys | 3 | 2015 | 260 | 0.080 |
Why?
|
| Health Planning | 1 | 2007 | 16 | 0.070 |
Why?
|
| Case Management | 1 | 2007 | 32 | 0.070 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2007 | 1 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 34 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2007 | 66 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 129 | 0.070 |
Why?
|
| Biomarkers | 2 | 2009 | 301 | 0.070 |
Why?
|
| Reproductive Medicine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Social Work | 1 | 2006 | 12 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2007 | 146 | 0.070 |
Why?
|
| Vaping | 1 | 2024 | 19 | 0.060 |
Why?
|
| Public Policy | 1 | 2024 | 17 | 0.060 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 6 | 0.060 |
Why?
|
| Social Norms | 1 | 2024 | 3 | 0.060 |
Why?
|
| Virus Replication | 2 | 2011 | 12 | 0.060 |
Why?
|
| Public Sector | 1 | 2003 | 9 | 0.060 |
Why?
|
| Urban Health | 1 | 2003 | 38 | 0.060 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 81 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 104 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2003 | 55 | 0.050 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 8 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 78 | 0.050 |
Why?
|
| Biopsy | 1 | 2013 | 74 | 0.050 |
Why?
|
| Melanoma | 1 | 2013 | 35 | 0.050 |
Why?
|
| Viral Load | 2 | 2011 | 135 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 212 | 0.050 |
Why?
|
| Confidentiality | 1 | 2022 | 27 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 64 | 0.050 |
Why?
|
| North America | 1 | 2012 | 42 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2012 | 64 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 48 | 0.050 |
Why?
|
| Patient Selection | 1 | 2013 | 190 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2002 | 99 | 0.050 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2013 | 28 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 375 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 154 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2002 | 305 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2021 | 10 | 0.050 |
Why?
|
| Communication | 1 | 2022 | 194 | 0.050 |
Why?
|
| Infection Control | 1 | 2020 | 10 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2012 | 124 | 0.050 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 39 | 0.050 |
Why?
|
| Temperance | 2 | 2012 | 24 | 0.050 |
Why?
|
| Counseling | 1 | 2022 | 189 | 0.040 |
Why?
|
| Naltrexone | 1 | 2020 | 17 | 0.040 |
Why?
|
| Lorazepam | 1 | 2019 | 4 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 36 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2009 | 2 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2009 | 6 | 0.040 |
Why?
|
| Triglycerides | 1 | 2009 | 86 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 202 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 223 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 119 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 130 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 30 | 0.040 |
Why?
|
| Risk | 1 | 2009 | 516 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2012 | 1097 | 0.040 |
Why?
|
| Death Certificates | 1 | 2017 | 19 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 201 | 0.040 |
Why?
|
| Oregon | 1 | 2017 | 171 | 0.030 |
Why?
|
| Military Personnel | 1 | 2006 | 12 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 17 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 93 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2006 | 4 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 304 | 0.030 |
Why?
|
| Inservice Training | 1 | 2015 | 14 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 351 | 0.030 |
Why?
|
| Leadership | 1 | 2015 | 39 | 0.030 |
Why?
|
| Vaccination | 1 | 2020 | 635 | 0.030 |
Why?
|
| Disease Progression | 1 | 2006 | 264 | 0.030 |
Why?
|
| Physicians | 1 | 2015 | 137 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2015 | 167 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2006 | 529 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 30 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 159 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 200 | 0.030 |
Why?
|
| African Americans | 1 | 2006 | 472 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 211 | 0.030 |
Why?
|
| Hospitals, Voluntary | 1 | 2012 | 4 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 10 | 0.030 |
Why?
|
| San Francisco | 1 | 2012 | 64 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 64 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 77 | 0.020 |
Why?
|
| Self Administration | 1 | 2011 | 9 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2011 | 25 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 18 | 0.020 |
Why?
|
| Morphine | 1 | 2009 | 8 | 0.020 |
Why?
|
| Time | 1 | 2009 | 20 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2009 | 47 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 256 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 709 | 0.020 |
Why?
|